Non-neurogenic bladder dysfunctions / / Matteo Balzarro, Vincenzo Li Marzi, editors

• Record Nr.: UNINA9910484096503321
• Pubbl/distr/stampa: Singapore : , : Springer, , [2021]; ©2021
• ISBN: 3-030-57393-1
• Descrizione fisica: 1 online resource (215 pages)
• Collana: Urodynamics, Neurourology and Pelvic Floor Dysfunctions
• Disciplina: 616.62
• Soggetti: Bladder - Diseases; Bufeta; Malalties de l'aparell urinari; Llibres electrònics
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Nota di contenuto: Intro -- Foreword -- Preface -- Preface -- Contents -- 1: Physiopathology of Overactive Bladder -- 1.1 Definitions -- 1.2 Pathophysiology -- 1.3 Neurogenic Factors -- 1.4 Non-neurogenic Factors -- 1.4.1 Myogenic Factor -- 1.4.2 Urotheliogenic Factor -- 1.4.3 Bladder Outlet Obstruction -- 1.4.4 Bladder Ischemia -- 1.4.5 Inflammation -- 1.4.6 Gender -- 1.4.7 Psychological Factors -- References -- 2: Diagnosis of Overactive Bladder -- 2.1 The Initial Diagnostic Workup in the Uncomplicated OAB Patient -- 2.1.1 History -- 2.1.2 Physical Examination -- 2.1.3 Urinalysis and Urine Culture -- 2.1.4 Voiding Diaries and Pad Testing -- 2.1.5 Symptom Questionnaires and Scores -- 2.2 The Diagnostic Workup in the Complicated OAB Patient -- 2.2.1 Cystoscopy -- 2.2.2 Urinary Tract Ultrasound -- 2.2.3 Uroflowmetry -- 2.2.4 Urodynamic Test -- References -- 3: Treatment Options in Patients with Overactive Bladder: Initial and Pharmacological Management -- 3.1 Introduction -- 3.2 Initial Management of Overactive Bladder -- 3.2.1 Lifestyle Modification -- 3.3 Pharmacological Treatment of Overactive Bladder Symptoms -- 3.3.1 Antimuscarinics Drugs -- 3.3.1.1 Darifenacin Hydrobromide -- 3.3.1.2 Fesoterodine Fumarate -- 3.3.1.3 ; Imidafenacin -- 3.3.1.4 Propantheline Bromide -- 3.3.1.5 Solifenacin Succinate -- 3.3.1.6 Tolterodine Tartrate -- 3.3.1.7 Trospium Chloride -- 3.3.1.8 Oxybutynin Chloride -- 3.3.1.9 Propiverine Hydrochloride -- 3.3.2 β-Adrenoceptor Agonists -- 3.3.2.1 Mirabegron -- 3.3.3 Antidepressants -- 3.3.3.1 Imipramine -- 3.4 Combination Therapy -- 3.5 Pharmacological Management of Patients with Overactive Bladder -- 3.5.1 Comorbidities -- 3.5.1.1 Glaucoma -- 3.5.1.2 Neurological Diseases -- 3.5.1.3 Cognitive Impairment -- 3.5.1.4 Associate BOO -- 3.5.1.5 Frail Older Patients -- References.; 4: Treatment Options in Patients with Overactive Bladder: The Invasive Management -- 4.1 Introduction -- 4.2 Botulinum Toxin -- 4.2.1 Molecular Structure and Mechanism of Action -- 4.2.2 BoNTA Intradetrusor Injection -- 4.2.3 BoNTA Efficacy -- 4.2.4 Adverse Events -- 4.3 Sacral Neuromodulation (SNM) -- 4.3.1 Technique -- 4.3.2 Mechanism of Action -- 4.3.3 SNM Efficacy -- 4.3.4 Adverse Events -- 4.4 Percutaneous Tibial Nerve Stimulation -- 4.4.1 PTNS Technique and Efficacy -- 4.5 Major Surgery -- 4.5.1 Enterocystoplasty -- References -- 5: Bladder Outlet Obstruction and Overactive Bladder in Females -- 5.1 Lower Urinary Tract Symptoms' Epidemiology -- 5.2 Bladder Outlet Obstruction Pathophysiology -- 5.3 OAB Pathophysiology -- 5.4 Diagnosis -- 5.4.1 History -- 5.4.2 Physical Examination -- 5.4.3 Diagnostic Tools -- 5.5 Management -- 5.6 OAB Management -- 5.7 BOO Management -- References -- 6: Bladder Outlet Obstruction and Overactive Bladder in Males -- 6.1 Definition -- 6.2 Epidemiology -- 6.3 Pathophysology -- 6.4 Diagnosis -- 6.4.1 General Considerations -- 6.5 Management -- 6.5.1 General Considerations -- 6.6 Conservative Treatments -- 6.6.1 General Considerations -- 6.7 Pharmacological Treatments -- 6.7.1 General Considerations -- 6.7.2 α1-Blockers and 5α-Reductase -- 6.7.3 Antimuscarinic Agents and Beta-3 Adrenoreceptors -- 6.7.4 Phosphodiesterase 5 Inhibitors -- 6.7.5 Plant Extracts: Phytotherapy -- 6.8 Surgical Treatments -- 6.8.1 General Considerations -- References -- 7: Overactive Bladder and Female Stress Urinary Incontinence -- 7.1 An Overview on "Urethrogenic" Mixed Urinary Incontinence -- 7.2 A Counterview on "Urethrogenic" Mixed Urinary Incontinence -- References -- 8: Physiopathology of Underactive Bladder -- 8.1 Introduction and Definitions -- 8.2 Physiopathology.; 8.2.1 Detrusor Muscle Activity Damage -- 8.2.2 Neurogenic Damage -- 8.2.3 Receptors Expression and Drugs -- 8.2.4 Idiopathic UAB -- 8.3 Aging -- 8.4 Fowler's Syndrome -- 8.5 Dysfunctional Voiding -- 8.6 Conclusions -- References -- 9: Diagnosis of Underactive Bladder in Male -- 9.1 Introduction -- 9.2 Clinical Findings -- 9.3 Urodynamic Testing -- 9.4 Conclusions -- References -- 10: Diagnosis of Underactive Bladder in Female -- 10.1 Diagnosis of Underactive Bladder in Females -- 10.2 Clinical Diagnosis -- 10.2.1 Medical History -- 10.2.2 Symptoms -- 10.2.3 Patient-Reported Outcomes -- 10.3 Urodynamics -- 10.3.1 Free Flow -- 10.3.2 Pressure/Flow Study -- 10.3.3 Detrusor Contraction Strength -- 10.3.3.1 Isovolumetric Detrusor Pressure -- 10.3.3.2 Watts Factor -- 10.3.3.3 Projected Isovolumetric Pressure (PIP) -- 10.3.4 Detrusor Contraction Velocity -- 10.3.5 The Role of Bladder Sensation -- 10.3.6 The Role of DO -- 10.4 Conclusion -- References -- 11: Treatment Options of Underactive Bladder -- 11.1 Conservative Management -- 11.2 Pharmacological Therapy -- 11.3 Minimally Invasive Treatment -- 11.4 Surgical Treatment -- 11.5 Conclusion -- References -- 12: Detrusor Overactivity with Detrusor Underactivity -- 12.1 Introduction -- 12.2 Etiology -- 12.3 Prevalence and Risk Factors -- 12.4 ; Diagnosis -- 12.5 Treatment -- 12.6 Conclusion -- References -- 13: Defunctionalized Bladder and Kidney Transplantation -- 13.1 Introduction -- 13.2 Pathophysiology -- 13.3 Clinical and Urodynamic Characteristics -- 13.4 Outcomes and Complications -- 13.5 Conclusions -- References -- 14: Imaging in Bladder Dysfunctions -- 14.1 Introduction -- 14.2 Urogynecology -- 14.2.1 Bladder US Findings in Urogynecology -- 14.2.1.1 PVR -- 14.2.1.2 BWT -- 14.2.2 Extravesical US Findings in Urogynecology.; 14.2.2.1 Urethral Hypermobility -- 14.2.2.2 Funneling -- 14.2.2.3 Pelvic Organ Prolapse (POP) -- 14.3 Male LUTS -- 14.3.1 Bladder US Findings in Male LUTS -- 14.3.1.1 PVR -- 14.3.1.2 BWT/DWT -- 14.3.1.3 UEBW -- 14.3.2 Prostate US Findings in Male LUTS -- 14.3.2.1 PCAR -- 14.3.2.2 IPP -- 14.3.2.3 PUA -- References -- 15: Female Sexuality in Pelvic Floor Disorders -- 15.1 Introduction and Epidemiology -- 15.2 Diagnosis -- 15.3 Screening Questionnaires -- 15.4 Screening for Sexual Activity and Function in Women with PFDs -- 15.5 Sexual Function in Specific Pelvic Floor Disorders -- 15.5.1 Pelvic Organ Prolapse -- 15.6 Nonsurgical Treatment of Pelvic Organ Prolapse -- 15.6.1 Pessaries -- 15.7 Surgical Treatment of Pelvic Organ Prolapse -- 15.7.1 Anterior and Posterior Repairs -- 15.7.2 Apical Repairs -- 15.8 Urinary Incontinence -- 15.9 Stress Urinary Incontinence -- 15.9.1 Pelvic Floor Physical Therapy (PFFT) -- 15.9.2 Colposuspension and Midurethral Slings -- 15.10 Urinary Urgency Incontinence and Overactive Bladder -- 15.10.1 Oral Medications -- 15.10.2 Neuromodulation -- 15.10.3 Intra-detrusor Botulinum Toxin A (Botox) -- 15.11 Anal and Fecal Incontinence -- 15.12 Surgical Treatment of Fecal Incontinence -- 15.12.1 Sphincteroplasty -- 15.12.2 Neuromodulation and Botox -- 15.13 Conclusion -- References -- Index.